TransMedics Group, Inc. (TMDX)
| Market Cap | 2.18B -28.8% |
| Revenue (ttm) | 635.89M +30.2% |
| Net Income | 171.92M +251.2% |
| EPS | 4.46 +216.8% |
| Shares Out | 34.56M |
| PE Ratio | 14.16 |
| Forward PE | 25.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,221,185 |
| Open | 61.72 |
| Previous Close | 62.04 |
| Day's Range | 61.40 - 64.35 |
| 52-Week Range | 60.11 - 156.00 |
| Beta | 2.06 |
| Analysts | Buy |
| Price Target | 131.30 (+107.75%) |
| Earnings Date | May 5, 2026 |
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung tra... [Read more]
Financial Performance
In 2025, TransMedics Group's revenue was $605.49 million, an increase of 37.13% compared to the previous year's $441.54 million. Earnings were $190.29 million, an increase of 436.58%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price target is $131.3, which is an increase of 107.75% from the latest price.
News
TransMedics downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded TransMedics (TMDX) to Perform from Outperform without a price target post the Q1 report. The cites “pure exhaustion defending this name” for the downgrade. The clinical value pr...
TransMedics price target lowered to $140 from $157 at Baird
Baird analyst David Rescott lowered the firm’s price target on TransMedics (TMDX) to $140 from $157 and keeps an Outperform rating on the shares. The firm updated its model following…
TransMedics price target lowered to $85 from $130 at Stifel
Stifel analyst Thomas Stephan lowered the firm’s price target on TransMedics (TMDX) to $85 from $130 and keeps a Hold rating on the shares.
TransMedics price target lowered to $124 from $152 at Canaccord
Canaccord analyst William Plovanic lowered the firm’s price target on TransMedics (TMDX) to $124 from $152 and keeps a Buy rating on the shares. The firm said they released a…
TransMedics price target lowered to $120 from $190 at TD Cowen
TD Cowen analyst Joshua Jennings lowered the firm’s price target on TransMedics (TMDX) to $120 from $190 and keeps a Buy rating on the shares. The firm said its Q1…
TransMedics price target lowered to $142 from $174 at Needham
Needham lowered the firm’s price target on TransMedics (TMDX) to $142 from $174 and keeps a Buy rating on the shares. The company’s Q1 revenue and earnings missed consensus estimates,…
TransMedics falls -20.5%
TransMedics (TMDX) is down -20.5%, or -$19.43 to $75.50.
TransMedics Group Earnings Call Transcript: Q1 2026
Q1 2026 delivered 21% revenue growth and strong operational execution, despite regulatory headwinds and donor supply volatility. Major investments in technology, logistics, and international expansion support a reiterated 2026 revenue guidance of $727–$757 million.
TransMedics Reports First Quarter 2026 Financial Results
ANDOVER, Mass., May 5, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...
TransMedics signs agreement to invest in PAD Aviation
TransMedics (TMDX) Group announced that it has entered into a definitive agreement to invest in PAD Aviation, a premier Germany-based private aviation operator. The proposed strategic investment is in...
TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH
Proposed strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, intended to lay the foundation for TransMedics to establish a dedicated organ transplantation...
TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting
Unveils New Controlled Hypothermic Organ Preservation System (CHOPS) to Expand its Product Portfolio and to Facilitate Enrollment in Control Arms of OCS ENHANCE Heart Part B and OCS DENOVO Lung Clinic...
TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026
ANDOVER, Mass., April 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics price target lowered to $118 from $170 at Evercore ISI
Evercore ISI lowered the firm’s price target on TransMedics (TMDX) to $118 from $170 and keeps an Outperform rating on the shares as part of the firm’s medical technology and…
TransMedics Group Transcript: Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Management outlined plans to deepen integration into the U.S. transplant ecosystem, highlighted robust clinical trial progress, and detailed ongoing European expansion and operational improvements. Regulatory decisions on further integration are expected by 2027, with significant growth anticipated in kidney and international markets.
TransMedics price target raised to $130 from $115 at Stifel
Stifel raised the firm’s price target on TransMedics (TMDX) to $130 from $115 and keeps a Hold rating on the shares. The firm updated models across its medical technology and…
TransMedics Group Transcript: TD Cowen 46th Annual Health Care Conference
OCS Kidney is positioned to address rising DGF rates and low kidney utilization, with a late 2025/early 2027 rollout. Next-gen OCS devices will drive margin expansion, while ongoing trials and regulatory changes offer growth opportunities. International expansion, especially in Europe, is a key focus.
TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results
ANDOVER, Mass., Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics price target raised to $168 from $154 at Baird
Baird analyst David Rescott raised the firm’s price target on TransMedics (TMDX) to $168 from $154 and keeps an Outperform rating on the shares. The firm updated its model following…
TransMedics price target raised to $170 from $155 at Evercore ISI
Evercore ISI raised the firm’s price target on TransMedics (TMDX) to $170 from $155 and keeps an Outperform rating on the shares.
TransMedics price target raised to $170 from $155 at Evercore ISI
Evercore ISI raised the firm’s price target on TransMedics (TMDX) to $170 from $155 and keeps an Outperform rating on the shares.
TransMedics price target raised to $175 from $150 at Oppenheimer
Oppenheimer analyst Suraj Kalia raised the firm’s price target on TransMedics (TMDX) to $175 from $150 and keeps an Outperform rating on the shares following quarterly results. The firm notes…
TransMedics price target raised to $149 from $114 at JPMorgan
JPMorgan analyst Allen Gong raised the firm’s price target on TransMedics (TMDX) to $149 from $114 and keeps a Neutral rating on the shares. The firm says the company’s inline…
TransMedics price target raised to $160 from $140 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on TransMedics (TMDX) to $160 from $140 and keeps an Overweight rating on the shares. The firm notes Transmedics reported…
TransMedics Group Earnings Call Transcript: Q4 2025
Delivered record 2025 results with 37% revenue growth, strong operating leverage, and robust cash flow. 2026 guidance targets 20–25% revenue growth, supported by clinical adoption, new programs, and international expansion, despite near-term margin pressures.